Peregrine Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Peregrine Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.43M	Sell	393,095 -93,546	-19%	-$1.43M	0.27%	115
2026 Q1	$6.75M	Buy	486,641 +34,139	+8%	+$544K	0.25%	120
2025 Q4	$7.35M	Sell	452,502 -70,300	-13%	-$1.15M	0.23%	127
2025 Q3	$7.82M	Sell	522,802 -179,909	-26%	-$2.19M	0.24%	118
2025 Q2	$8.19M	Buy	+702,711	New	+$6.38M	0.25%	110
2024 Q2	–	Sell	-375,716	Closed	-$1.21M	–	326
2024 Q1	$1.21M	Buy	375,716 +78	+0%	+$302	0.03%	264
2023 Q4	$1.84M	Sell	375,638 -64,317	-15%	-$293K	0.06%	245
2023 Q3	$2.4M	Sell	439,955 -27,331	-6%	-$181K	0.07%	247
2023 Q2	$3.14M	Sell	467,286 -109	-0%	-$810	0.09%	247
2023 Q1	$4.13M	Buy	467,395 +199,764	+75%	+$1.76M	0.12%	243
2022 Q4	$2.04M	Sell	267,631 -11,100	-4%	-$86.4K	0.06%	241
2022 Q3	$1.99M	Sell	278,731 -15,222	-5%	-$143K	0.06%	245
2022 Q2	$2.38M	Sell	293,953 -24,192	-8%	-$213K	0.07%	252
2022 Q1	$4.42M	Sell	318,145 -21,316	-6%	-$335K	0.1%	248
2021 Q4	$9.53M	Buy	339,461 +62,118	+22%	+$1.9M	0.19%	209
2021 Q3	$9.43M	Sell	277,343 -44,578	-14%	-$1.61M	0.2%	218
2021 Q2	$13.2M	Buy	321,921 +37,628	+13%	+$1.46M	0.24%	200
2021 Q1	$11.4M	Sell	284,293 -12,513	-4%	-$677K	0.21%	223
2020 Q4	$17.6M	Sell	296,806 -30,424	-9%	-$1.57M	0.33%	108
2020 Q3	$15.9M	Sell	327,230 -45,817	-12%	-$1.93M	0.42%	89
2020 Q2	$18M	Sell	373,047 -12,543	-3%	-$457K	0.51%	68
2020 Q1	$10.7M	Buy	385,590 +90,041	+30%	+$2.51M	0.38%	109
2019 Q4	$8.84M	Buy	+295,549	New	+$8.49M	0.23%	158

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Peregrine Capital Management's ADPT Position: Q2 2026 in Review

Peregrine Capital Management reduced its Adaptive Biotechnologies (ADPT) stake by 19% in Q2 2026, selling an estimated $1.43M and leaving 393,095 shares worth $8.43M. The position accounts for 0.27% of the portfolio, ranked #115.

Peregrine Capital Management first reported a position in ADPT in Q4 2019 and has held it in 23 quarters since. The position peaked at $18M in Q2 2020. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Peregrine Capital Management held 393,095 shares of Adaptive Biotechnologies worth $8.43M as of Q2 2026.
Peregrine Capital Management sold 93,546 Adaptive Biotechnologies shares in Q2 2026, an estimated $1.43M.
Adaptive Biotechnologies made up 0.27% of Peregrine Capital Management's portfolio in Q2 2026, its #115 holding.
Peregrine Capital Management first reported a position in Adaptive Biotechnologies in Q4 2019 and has held it in 23 quarters since.
Peregrine Capital Management's Adaptive Biotechnologies position peaked at $18M in Q2 2020.
300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Peregrine Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.